Skip to main content

Table 1 Demographic and baseline characteristics of the diabetes, CKD, and chronic CVD subgroups (randomized set)

From: Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study

  Diabetes (n=387) CKD (n=103) Chronic CVD (n=227)
  OM 40/ AML 10 mg OM 40/ HCTZ 25 mg AML 10/ HCTZ 25 mg OM 40/ AML 10/ HCTZ 25 mg OM 40/ AML 10 mg OM 40/ HCTZ 25 mg AML 10/ HCTZ 25 mg OM 40/ AML 10/ HCTZ 25 mg OM 40/ AML 10 mg OM 40/ HCTZ 25 mg AML 10/ HCTZ 25 mg OM 40/ AML 10/ HCTZ 25 mg
  (n=100) (n=99) (n=92) (n=96) (n=29) (n=25) (n=29) (n=20) (n=56) (n=61) (n=55) (n=55)
Age, mean (SD), yrs 59.7 (8.9) 60.3 (8.7) 56.5 (9.4) 58.1 (9.4) 71.0 (7.8) 71.5 (9.4) 69.4 (9.5) 68.1 (10.0) 60.2 (11.2) 61.1 (9.8) 58.2 (11.0) 58.6 (10.9)
Male, n (%) 60 (60.0) 54 (54.5) 52 (56.5) 51 (53.1) 9 (31.0) 10 (40.0) 10 (34.5) 5 (25.0) 40 (71.4) 38 (62.3) 34 (61.8) 39 (70.9)
Ethnicity  
Hispanic/Latino, n (%) 21 (21.0) 18 (18.2) 13 (14.1) 15 (15.6) 1 (3.4) 2 (8.0) 3 (10.3) 2 (10.0) 8 (14.3) 5 (8.2) 7 (12.7) 8 (14.5)
Race  
White, n (%) 72 (72.0) 73 (73.7) 58 (63.0) 67 (69.8) 18 (62.1) 19 (76.0) 21 (72.4) 13 (65.0) 40 (71.4) 45 (73.8) 37 (67.3) 35 (63.6)
Black, n (%) 26 (26.0) 24 (24.2) 29 (31.5) 25 (26.0) 9 (31.0) 5 (20.0) 7 (24.1) 6 (30.0) 16 (28.6) 16 (26.2) 18 (32.7) 17 (30.9)
Obesity, n (%)* 77 (77.0) 74 (74.7) 71 (77.2) 73 (76.0) 9 (31.0) 2 (8.0) 7 (24.1) 6 (30.0) 32 (57.1) 40 (65.6) 35 (63.6) 33 (60.0)
Hypertension duration, mean (SD), y 12.8 (9.6) 13.2 (10.5) 11.2 (9.6) 10.7 (9.8) 12.1 (8.0) 14.0 (10.0) 13.0 (9.3) 14.8 (14.4) 12.0 (8.0) 15.0 (12.3) 12.9 (9.9) 13.3 (11.0)
Baseline BP, mean (SD), mm Hg 172.2/98.6 (13.5/7.5) 173.1/97.8 (14.7/7.6) 170.7/99.3 (13.6/6.7) 170.7/98.3 (16.0/6.9) 174.4/96.4 (12.5/8.8) 172.2/96.0 (11.6/7.6) 172.9/97.4 (17.1/6.6) 173.8/96.6 (16.5/6.5) 173.4/101.0 (16.2/10.6) 172.8/99.3 (11.7/9.3) 174.2/100.8 (16.7/7.1) 171.7/100.4 (11.0/9.1)
  1. *BMI ≥30 kg/m2.
  2. AML, amlodipine; BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SD, standard deviation.